Trial Profile
A randomised, double-blind, placebo controlled, crossover dose-ranging study to investigate the effect of rosuvastatin (CRESTOR) on high density lipoprotein kinetics in patients with the metabolic syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 01 Aug 2008 Results have been published in Diabetes Care.
- 06 Dec 2006 Status change
- 23 Nov 2005 New trial record.